Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction (KaRen)

August 6, 2019 updated by: Donal Erwan, French Cardiology Society

Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction: Prevalence, Characterisation and Prognostic Significance of Cardiac Desynchrony

The purpose of this study is to examine electrical and echocardiographic characteristics and prognosis of consecutive patients admitted with acute heart failure and diagnosed to have heart failure with preserved ejection fraction (HFPEF).

Study Overview

Status

Completed

Conditions

Detailed Description

  • Time 0: Patients will be screened at the time of presentation to the hospital at participating centres
  • Usually patients will be hospitalised for an acute dyspnea in relation with a pulmonary congestion. This congestion does not necessarily justify a hospitalization and for part of the patients a consultation and a dedicated treatment would be good enough to cure the symptoms.
  • Thus, patients seen in emergency for a congestion and diagnosed or known to have a preserved left ventricular ejection fraction (LV EF > 45%) will be proposed to participate to the study.
  • Patients meeting inclusion criteria will be invited back to the clinic in stable condition, approximately 4-8 weeks after the initial hospitalization.
  • Time 4-8 weeks after initial hospitalisation (NOT after discharge): Comprehensive history-taking and examinations.
  • Any information necessary for the study will be collected by the principal investigator in each participating center in a dedicated, secure, e-CRF. The access to the e-CRF will be restrictive to the only principal investigator of each center. The lonely other persons able to take look to the e-CRF are the study monitors.
  • Time 6, 12, and 18 months: Follow up by phone call or review of charts or other records such as death registries. This part of the study will be performed by the CRAs in the French Society of Cardiology

Study Type

Observational

Enrollment (Actual)

362

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Rennes, France, 35000
        • Pontchaillou Hospital
  • Sweden
      • Stockholm, Sweden
        • Karolinska University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients presenting to the hospital with congestive heart failure

Description

Inclusion Criteria:

  • Patient presenting to the hospital with congestive heart failure, defined as:

    1. Clinical signs of heart failure

      Major criteria

      • Paroxysmal nocturnal dyspnea
      • Orthopnea
      • Jugular venous distension
      • Pulmonary crackling rales
      • 3rd heart sound
      • Cardiothoracic ratio > 0.5 on X-ray
      • Pulmonary oedema on X-ray

      Minor Criteria

      • peripheral oedema
      • nocturnal cough
      • dyspnoea at exercise
      • hepatomegaly
      • pleural effusion
      • tachycardia (defined as ≥ 100 beats per minute)

      Heart failure if: presence of 2 major criteria or 1 major + 2 minor criteria

    2. LVEF ≥ 45% by echocardiography within 72h

    3. BNP > 100 ng/L or NT-proBNP > 300 ng/L

      Exclusion Criteria:

  • Evidence of primary hypertrophic or restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease
  • Known cause of right heart failure not related to left ventricular dysfunction
  • Pericardial constriction
  • Clinically significant pulmonary disease, as evidenced by requirement of home oxygen.
  • End-stage renal disease requiring dialysis
  • Bi-ventricular pacemaker (CRT)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients with HF
Each patient seen in hospital emergency or for congestive heart failure and with an ejection fraction above 45%

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Death rate
Time Frame: 18 months
Analyse survival (all-cause death)
18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hospitalization for HF
Time Frame: 18 months
Hospitalization for Heart Failure
18 months
Cardiovascular death
Time Frame: 18 months
Cardiovascular death
18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

French Cardiology Society

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 1, 2008

Primary Completion (ACTUAL)

December 1, 2012

Study Completion (ACTUAL)

December 1, 2012

Study Registration Dates

First Submitted

March 8, 2010

First Submitted That Met QC Criteria

March 23, 2010

First Posted (ESTIMATE)

March 24, 2010

Study Record Updates

Last Update Posted (ACTUAL)

August 8, 2019

Last Update Submitted That Met QC Criteria

August 6, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 08140

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Congestive Heart Failure

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe